AstraZeneca’s SATURN “Moon Shot” Pitting Crestor Against Lipitor Misses The Mark

Top-line results from AstraZeneca’s SATURN trial in atherosclerosis seem unlikely to prevent erosion of Crestor’s (rosuvastatin) market share once generic versions of Pfizer’s Lipitor (atorvastatin) enter the market in November.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet